MIRA Pharmaceuticals, Inc. - 10-Q Summary (Q2 2024)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company focused on two neuroscience programs: Ketamir-2 (an oral ketamine analog for treatment-resistant depression) and MIRA-55 (an oral pharmaceutical marijuana candidate for neuropathic pain and cognitive decline). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(1,691,325) | $(3,409,096) | $(2,607,152) |
| Loss Per Share (Diluted) | $(0.11) | $(0.23) | $(0.20) |
| Cash and Equivalents (End of Period) | $2,823,781 | $2,823,781 | $24,823 |
| Operating Cash Flow (YTD) | $(1,913,465) | $(1,913,465) | $(1,736,119) |
| Total Assets | $3,015,578 | $3,015,578 | $4,932,443 (Dec 31, 2023) |
| Total Liabilities | $796,612 | $796,612 | $558,097 (Dec 31, 2023) |
Debt and Liquidity: The company has no outstanding debt from its $3.0 million related-party loan facility with MIRALOGX as of June 30, 2024. A small amount of accrued interest ($14,472) is owed to related parties. The company reported a net cash burn of approximately $1.9 million for the six months ended June 30, 2024.
Material Changes vs. Prior Period
- Increased Operating Costs: Total operating costs for the six months ended June 30, 2024, were $3.5 million, compared to $2.3 million in the same period in 2023. This increase is primarily driven by higher Research and Development (R&D) expenses ($1.4M vs. $0.2M net in 2023) and General and Administrative (G&A) expenses ($2.1M vs. $1.7M in 2023).
- R&D Shift: R&D expenses in 2023 included significant credits ($0.4M) due to unperformed vendor milestones. In 2024, the company incurred actual costs for pre-clinical research on Ketamir-2.
- Elimination of Related Party Travel: Related party travel costs dropped to $0 in 2024, down from $0.5 million in 2023, following the termination of a shared aircraft lease in March 2023.
- Interest Income vs. Expense: The company shifted from net interest expense in 2023 (due to debt issuance costs) to net interest income of $0.09 million in 2024, driven by money market account yields.
Guidance, Outlook, and Risks
Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for 12 months following the report date. With cash of approximately $2.8 million and a burn rate of ~$1.9 million per six months, the company expects to fund operations only through the fourth quarter of 2024 without additional financing.
Outlook and Strategy:
- The company has identified MIRA-55 as its lead compound for oral pharmaceutical marijuana, superseding MIRA1a, and has filed a provisional patent.
- Development of Ketamir-2 continues with pre-clinical research payments made in Q2.
- The company filed a shelf registration statement (Form S-3) on August 12, 2024, to facilitate future equity raises.
Risks and Contingencies:
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses, though remediation efforts (hiring experienced accounting personnel) are underway.
- Regulatory and Third-Party Reliance: The company relies on Contract Research Organizations (CROs) for pre-clinical trials. Delays or failures by these third parties could impact the timeline for Investigational New Drug (IND) filings.
- Related Party Dependence: Significant reliance on related parties (Bay Shore Trust, MIRALOGX) for licensing, potential funding, and historical operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.8 million cash balance against the projected burn rate to confirm the "fourth quarter 2024" funding horizon.
- Financing Plans: Review the status of the Form S-3 shelf registration filed in August 2024 and any subsequent equity offerings.
- Internal Controls: Monitor future filings for updates on the remediation of material weaknesses in internal controls over financial reporting.
- Related Party Transactions: Scrutinize the terms of the $3.0 million loan facility with MIRALOGX and the exclusive license agreement for Ketamir-2.
- Product Development: Confirm the status of the provisional patent for MIRA-55 and the timeline for IND filing for Ketamir-2.